30.06.2015 • NewsDede WillamsFinancial Times

Private Equity Said to Eye North Africa Health Market

Private equity groups are increasingly eyeing opportunities in North Africa’s healthcare market, attracted by expanding populations spending more out of their own pockets on private medical services in countries where state provision is inadequate or underfunded, says the UK business newspaper Financial Times (FT).
UAE-based Abraaj, which has $9 billion of assets under management, according to the newspaper, has teamed up this year with three development institutions to establish a $200 million healthcare investment platform, the North Africa Hospital Holdings Group, focused on Egypt and Tunisia.
Abraaj, which already has stakes in hospitals in the two countries, is the biggest contributor to the fund with $145 million. The group’s three partners in the fund are the European Bank for Reconstruction and Development, Germany’s DEG and France’s Proparco.
Across North Africa, government-provided healthcare is falling behind demand, according to research cited by Abraaj. Out-of-pocket expenses by the region’s citizens on medical services averaged 41% of healthcare spending. In Egypt, it is 63%, a regional bank’s report said.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.